Receptor de Androgénio
O receptor de andrógenos (AR) é um receptor hormonal nuclear que é ativado pela ligação a andrógenos, como a testosterona e a diidrotestosterona. Este receptor desempenha um papel crucial no desenvolvimento e na manutenção das características masculinas, bem como na regulação de vários processos fisiológicos, incluindo o crescimento muscular, a libido e a densidade óssea. Inibidores do receptor de andrógenos são amplamente estudados no contexto do câncer de próstata, onde a sinalização do AR é frequentemente aumentada. Na CymitQuimica, oferecemos uma gama de moduladores do receptor de andrógenos de alta qualidade para apoiar sua pesquisa em endocrinologia, biologia do câncer e regulação hormonal.
Foram encontrados 234 produtos para "Receptor de Androgénio".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JNJ-1250132
CAS:JNJ-1250132 is a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro.Fórmula:C33H41NO4Cor e Forma:SolidPeso molecular:515.68SC428
CAS:SC428 acts as an inhibitor of the androgen receptor (AR), specifically targeting the N-terminal domain of AR. This compound effectively diminishes the transactivation of various AR forms, including AR-V7, ARv567es, full-length AR (AR-FL), and its LBD mutants. Additionally, SC428 significantly inhibits AR-FL nuclear translocation, chromatin binding, and AR-regulated gene transcription under androgen stimulation. In vitro, SC428 suppresses the proliferation of tumor cells. In vivo, it inhibits tumor growth in mice transplanted with 22Rv1 cells by inducing apoptosis.Fórmula:C15H10F3N3OSCor e Forma:SolidPeso molecular:337.32Pentomone
CAS:Pentomone (LY-113935) is an anti-androgen compound that acts as a prostate growth inhibitor.Fórmula:C24H26O5Cor e Forma:SolidPeso molecular:394.46(Rac)-Idroxioleic acid sodium
CAS:(Rac)-Idroxioleic acid (2-Hydroxyoleic acid) sodium is a synthetic derivative of oleic acid (OA) that binds to the plasma membrane, altering lipid composition. This compound exhibits antitumor properties.Fórmula:C18H33NaO3Cor e Forma:SolidPeso molecular:320.44FL442
CAS:FL442 is an Androgen Receptor (AR) modulator. This compound exhibits potent inhibitory effects in AR-dependent prostate cancer cells, showing similar suppression efficiency to the traditional antiandrogen drugs Bicalutamide and Enzalutamide. It also maintains antiandrogen activity against the Enzalutamide-resistant AR mutant F876L. The pharmacokinetic properties of FL442 in mice reveal a longer half-life (8 hours), excellent targeting (prostate tissue), and metabolic stability. Additionally, it is effective at inhibiting LNCaP tumor growth at low plasma concentrations (30 ng/mL).Fórmula:C15H13F3N2OCor e Forma:SolidPeso molecular:294.27AR antagonist 11
CAS:AR antagonist 11 (Compound c2) is a selective androgen receptor antagonist with an IC50 of 0.019 μM. It is also effective against the ARF877L/T878A mutant (IC50: 1.03 μM). Additionally, AR antagonist 11 inhibits LNCaP cell proliferation and decreases PSA protein expression (IC50: 0.54 μM). This compound is applicable in prostate cancer (PCa) research.Fórmula:C20H17ClN2OCor e Forma:SolidPeso molecular:336.815(+)-JJ-74-138
CAS:(+)-JJ-74-138 is a novel non-competitive androgen receptor (AR) antagonist capable of inhibiting enzalutamide-resistant castration-resistant prostate cancer (CRPC).Fórmula:C22H22F8N2OSCor e Forma:SolidPeso molecular:514.48LX1
CAS:LX1, an anti-prostate cancer compound, specifically targets the androgen receptor (AR), AR variants, and the steroidogenic enzyme AKR1C3. It inhibits AKR1C3's enzymatic function, decreases the conversion of androstenedione to testosterone, and reduces the expression of both AR and AR-V7, subsequently downregulating their target genes. Additionally, LX1 is effective in overcoming tumor cell resistance to Enzalutamide, and when combined with Enzalutamide, it further suppresses tumor growth.Fórmula:C22H15F6NO2Cor e Forma:SolidPeso molecular:439.35AR antagonist 10
CAS:AR antagonist 10 (Compound Y5) is a potent, orally active androgen receptor (AR) antagonist with an IC50 value of 0.04 μM. It demonstrates a dual mechanism of action: antagonizing AR by disrupting AR dimerization and inducing AR degradation through the ubiquitin-proteasome pathway. This compound shows excellent activity against various resistant AR mutants and effectively inhibits the growth of LNCaP xenograft tumors. AR antagonist 10 is applicable for research in resistant prostate cancer.Fórmula:C18H17ClN4O3SCor e Forma:SolidPeso molecular:404.871GLPG0492 (R enantiomer)
CAS:GLPG0492 R enantiomer is the R enantiomer of GLPG-0492, a novel selective androgen receptor modulator.Fórmula:C19H14F3N3O3Cor e Forma:SolidPeso molecular:389.33Androgen receptor ligand 1
CAS:Androgen receptorligand 1 is a ligand for the androgen receptor (AR). It interacts with the CRBN E3 ligase via a linker to form an AR-PROTAC degrader. This compound is useful in prostate cancer research.Fórmula:C19H16F4N2OCor e Forma:SolidPeso molecular:364.34Androgen receptor antagonist 12
CAS:Compound EF2 (Androgen receptor antagonist 12) is an orally active antagonist of the androgen receptor (AR) with an IC50 of 0.30 µM. It inhibits the transcriptional activity of mutant AR and the proliferation of AR-positive PCa (prostate cancer) cell lines. Additionally, Compound EF2 blocks the nuclear translocation of AR and suppresses tumor growth in the C4-2B xenograft mouse model. This compound is used for research in prostate cancer.Fórmula:C12H8F3N3O2Cor e Forma:SolidPeso molecular:283.21SJ1008066
CAS:SJ1008066 is a MAGE-A11 inhibitor with an IC50 of 0.13 μM. It binds to the MAGE homology domain (MHD) and disrupts the MAGE-A11:PCF11 interaction.Fórmula:C21H22N4Cor e Forma:SolidPeso molecular:330.43VNPP433-3β
CAS:VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.Fórmula:C29H34N4Cor e Forma:SolidPeso molecular:438.61AR/BET protein degrader-1
CAS:AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.Fórmula:C43H44N6O5Cor e Forma:SolidPeso molecular:724.85PF-06260414
CAS:PF-06260414 is a non-steroidal SARM and androgen receptor partial agonist that promotes muscle protein synthesis and is used in muscle atrophy research.Fórmula:C14H14N4O2SPureza:97.69% - 98.99%Cor e Forma:SolidPeso molecular:302.35Androstatrione
CAS:Androstatrione is an androgenic compound.Fórmula:C19H26O3Cor e Forma:SolidPeso molecular:302.41Androgen receptor degrader-2
CAS:Androgen Receptor Degrader-2 (Compound 9) is a potent degrader of androgen receptors, with potential application in cancer research [1].Fórmula:C16H16ClN3O4Pureza:98%Cor e Forma:SolidPeso molecular:349.77ERβ agonist-1
CAS:ERβagonist-1 (Compound 8) functions as a dual-active selective ERβ agonist (EC50: 46.8 nM) and an AR antagonist (IC50: 1555 nM). By binding to ERβ, it activates its signaling pathways while simultaneously inhibiting AR activity. Retaining selective ERβ agonist activity in mouse models, ERβagonist-1 is applicable in prostate cancer research.Fórmula:C25H36O2Cor e Forma:SolidPeso molecular:368.552-Ethylhexyl(E)-3-(4-(methoxy-D3) phenyl)acrylate
CAS:2-Ethylhexyl(E)-3-(4-(methoxy-D3) phenyl)acrylate is the deuterated form of Octinoxate. Octinoxate (Octyl methoxycinnamate) acts as an agonist of thyroid hormone receptors, leading to a reduction in triiodothyronine (T3) and thyroxine (T4) levels, as well as the transcription levels of type II deiodinase (deio2) related genes in Japanese Medaka. Commonly used as a safe ultraviolet (UV) filter in aquatic environments, Octinoxate inhibits CYP1A1 and CYP1B1, and influences hyaluronic acid (HA) metabolism in human keratinocytes through a PI3K pathway-dependent manner. It also exhibits both anti-estrogenic and anti-androgenic effects in vitro and in vivo.Fórmula:C18H26O3Peso molecular:293.42
